NMIBC: Clinical Trials

28 trials for NMIBC, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 recruiting, 8 not yet recruiting, 4 completed, 2 active not recruiting. 11 Phase 1, 9 Phase 2, 5 Not applicable, 4 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 111Not yet recruiting 4, Completed 3, Recruiting 2, Active not recruiting 1, Terminated 1
Phase 29Not yet recruiting 5, Recruiting 2, Active not recruiting 1, Completed 1
Not applicable5Recruiting 3, Not yet recruiting 2
Phase 34Recruiting 3, Withdrawn 1

Follow NMIBC: new trials by email Literature Review of NMIBC trials Research Report on NMIBC

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Outcomes for IR and High Risk (HR) Non-muscle Invasive Bladder Cancer (NMIBC) and ctDNA-based Biomarkers for Response and Recurrence in Muscle Invasive Bladder Cancer (MIBC)
This is a non-interventional, observational, prospective study. - NMIBC, MIBC
Not yet recruitingBladder Cancer Advocacy Network14002027-03-012026-10-26
Diagnostic Performance of Multiparametric Magnetic Resonance Imaging After Transurethral Resection of Bladder Tumour for Prediction of Muscle Invasion and Detection of Residual Tumour in Non-muscle-invasive Bladder Cancer Patients
Multiparametric Magnetic Resonance Imaging of the Bladder - Urinary Bladder Cancer, NMIBC
Not applicableNot yet recruitingUniversity of Lausanne Hospitals862026-12-012026-11-09
Trop2-Targeted Near-Infrared Fluorescence Imaging-Guided Precise Resection of Non-Muscle Invasive Bladder Cancer
TTP-ICG NIR fluorescent diagnostic agent - NMIBC
Phase 1 / Phase 2Not yet recruitingYunnan Cancer Hospital302026-10-302026-09-24
Feasibility of Automatic, Laser-based Distance Control in Persons With Superficial Bladder Tumors
ATLAS system - NMIBC
Not applicableRecruitingOptheras AS252026-10-022026-10-06
A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC
UGN-501 - Bladder (Urothelial, Transitional Cell) Cancer, NMIBC
Phase 1RecruitingUroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.302026-09-282026-10-13
Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC)
Non-Muscle Invasive Bladder Cancer, NMIBC
RecruitingNatera, Inc.4002026-07-272026-08-13
A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC
SHR-1501 for Injection, BCG for Injection, Epirubicin Hydrochloride for Injection - NMIBC
Phase 3RecruitingSuzhou Suncadia Biopharmaceuticals Co., Ltd.2362026-07-132026-07-20
1 Year Recurrence After Modified en Bloc Resection (ERBT) vs Transurethral Resection (TURBT) for Large Bladder Tumors
En Bloc Resection of Bladder Tumor, Trans Urethral Resection of Bladder Tumor - NMIBC, TCC
Phase 3Recruitingdmitry enikeev1362026-06-082026-10-27
ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer
BCG (50 mg) plus ANKTIVA (400 µg), BCG (50 mg) - NMIBC
Phase 3WithdrawnImmunityBio, Inc.2026-05-152026-05-19
The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.
SPGL008 - NMIBC
Phase 1 / Phase 2Not yet recruitingShenyang Sunshine Pharmaceutical Co., LTD.1202026-03-122026-03-03
DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC
Active Comparator: BCG induction and maintenance, DV + BCG induction and maintenance - Bladder (Urothelial, Transitional Cell) Cancer, NMIBC
Phase 3RecruitingFudan University1822025-12-012026-07-21
ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG
Intravesical Recombinant Mycobacterium (rMBCG) - NMIBC
Phase 1 / Phase 2RecruitingImmunityBio, Inc.402025-10-152026-03-27
Anesthesia Modality and Oncologic Outcomes in High-Risk NMIBC: A Randomized Trial
Spinal Anesthesia, General Anesthesia - NMIBC, TURBT
Not applicableNot yet recruitingNational Taiwan University Hospital3702025-08-012025-05-21
A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.
Gemcitabine + BCG, BCG (TICE strain) - NMIBC, Non-Muscle Invasive Bladder Urothelial Carcinoma
Phase 1 / Phase 2Not yet recruitingQueen's University312025-08-012025-07-17
A Bladder-Sparing Treatment Strategies of Large-Volume Non-Muscle-Invasive Bladder Cancer
bladder sparing set, RC - Bladder Cancer, NMIBC
Not applicableRecruitingThe First Affiliated Hospital with Nanjing Medical University602024-12-012025-03-18
SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt
SHR-1501+SHR-2005 - NMIBC
Phase 1 / Phase 2Not yet recruitingFudan University582024-10-012024-09-19
A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.
Distitamab Vedotin in combination with Tislelizumab - NMIBC
Phase 2Not yet recruitingFujian Medical University Union Hospital402024-10-012024-10-10
Immediate Chemotherapy Following Resection for High-Risk Non-Muscle-Invasive Bladder Cancer
Immediate postoperative chemotherapy - NMIBC
Not applicableRecruitingChanghai Hospital722024-06-012025-03-21
A Multicenter Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Microscopic Residual Disease (MRD)
NMIBC, MIBC
RecruitingPeking University First Hospital3002024-03-012025-05-28
A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer
ZH9 - NMIBC, High Risk NMIBC
Phase 1CompletedProkarium Ltd222024-01-082026-10-14

Showing 20 of 28. Sign in to see all of them.

Narrower conditions

Non-Muscle Invasive Bladder Neoplasms (28)  ·  Urinary Bladder Neoplasms (10)  ·  Neoplasms (5)  ·  Carcinoma, Transitional Cell (2)  ·  Recurrence (2)  ·  Carcinoma in Situ (1)  ·  Disease Progression (1)  ·  Neoplasm, Residual (1)

Broader conditions

Carcinoma (28)  ·  Female Urogenital Diseases (28)  ·  Female Urogenital Diseases and Pregnancy Complications (28)  ·  Male Urogenital Diseases (28)  ·  Neoplasms by Histologic Type (28)  ·  Neoplasms by Site (28)  ·  Neoplasms, Glandular and Epithelial (28)  ·  Urinary Bladder Diseases (28)  ·  Urogenital Diseases (28)  ·  Urogenital Neoplasms (28)  ·  Urologic Diseases (28)  ·  Urologic Neoplasms (28)  ·  Neoplasms (23)  ·  Urinary Bladder Neoplasms (18)  ·  Pathologic Processes (3)

Interventions

Gemcitabine (4)  ·  Anesthesia, General (1)  ·  Anesthesia, Spinal (1)  ·  BCG Vaccine (1)  ·  Epirubicin (1)  ·  Imiquimod (1)  ·  Injections (1)  ·  Maintenance (1)  ·  Mitomycin (1)  ·  Prospective Studies (1)  ·  enfortumab vedotin (1)  ·  hydroxycamptothecinum (1)  ·  pemigatinib (1)  ·  pirarubicin (1)  ·  tislelizumab (1)

Sponsors

ImmunityBio, Inc. (3)  ·  Fudan University (2)  ·  Astellas Pharma Global Development, Inc. (1)  ·  Aura Biosciences (1)  ·  Bladder Cancer Advocacy Network (1)  ·  Changhai Hospital (1)  ·  Ding-Wei Ye (1)  ·  Fujian Medical University Union Hospital (1)  ·  Insel Gruppe AG, University Hospital Bern (1)  ·  Natera, Inc. (1)  ·  National Taiwan University Hospital (1)  ·  Optheras AS (1)  ·  Peking University First Hospital (1)  ·  Prokarium Ltd (1)  ·  Queen's University (1)

Countries

China (10)  ·  United States (10)  ·  Canada (2)  ·  Spain (2)  ·  Australia (1)  ·  Denmark (1)  ·  France (1)  ·  Germany (1)  ·  Israel (1)  ·  Italy (1)  ·  Taiwan (1)  ·  United Kingdom (1)

Top investigators

Sebastian Mirkin, MD (2)  ·  Dingwei Ye, MD (1)  ·  Josefin-Beate Holz, MD (1)  ·  Noah M Hahn, MD (1)  ·  Shuxiong Zeng, M.D. Ph.D (1)  ·  Yair Lotan, MD (1)

Results publications

PMID 28705539, PMID 29801011, PMID 34511303, PMID 37414705, PMID 38142702, PMID 41314851

NIH funding

2023 (1)